Please login to the form below

Not currently logged in
Email:
Password:

melanoma drug

This page shows the latest melanoma drug news and features for those working in and with pharma, biotech and healthcare.

BMS' Yervoy picks up another indication in Europe

BMS' Yervoy picks up another indication in Europe

The EU green light will be welcomed news after BMS saw the big-selling melanoma drug flop in a head-to-head trial with Merck &Co’s Keytruda (pembrolizumab), which was ... melanoma is an outcome of BMS’s unyielding commitment to advancing treatments

Latest news

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    Novartis scores but Roche misses in melanoma trials. Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. ... indicates that the drugs could "transform the standard of care in the melanoma adjuvant setting".

  • BMS wins first US immuno-oncology paediatric licence BMS wins first US immuno-oncology paediatric licence

    The Food and Drug Administration (FDA) approved an expanded licence for Yervoy (ipilimumab) that will allow its use to treat unresectable or metastatic melanoma in patients aged 12 and older. ... led analysts at EvaluatePharma to predict that Merck

  • Opdivo tops Yervoy in adjuvant melanoma trial Opdivo tops Yervoy in adjuvant melanoma trial

    Opdivo tops Yervoy in adjuvant melanoma trial. BMS’nivolumab reduced the recurrence rate of melanoma compared to Yervoy. ... Opdivo (nivolumab) reduced the recurrence rate for patients with high-risk, advanced-stage melanoma who received the drug along

  • Novartis gets lung cancer OK for Tafinlar/Mekinist combo Novartis gets lung cancer OK for Tafinlar/Mekinist combo

    Novartis' cancer duo Tafinlar and Mekinist have been given the go-ahead in the EU as a treatment for non-small cell lung cancer (NSCLC), extending the use of the drug ... inhibitor - in combination with Tafinlar/Mekinist in melanoma patients, and also

  • Opdivo drives gain in BMS sales, but business revamp coming Opdivo drives gain in BMS sales, but business revamp coming

    Immuno-oncology drug Opdivo led the charge at Bristol-Myers Squibb in the third quarter with a three-fold hike in sales, despite its recent setback in first-line lung cancer. ... BMS' other growth products also contributed to the sales gains, with

More from news
Approximately 2 fully matching, plus 71 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics